1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
621EFB871E9946E70852577B20042535E
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/patient-advocacy-groups-communication-practices-and-structuring?opendocument
18
19opendocument
2018.205.176.100
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




Products & Services Medical Affairs Patient Advocacy

Working with Patient Advocacy Groups: Effective Approaches to Advocacy Communication and Structure

ID: 5104


Features:

Metrics, Graphics


Pages/Slides: 33


Published: Pre-2014


Delivery Format: Online PDF Document


 

License Options:
close

Single User: Authorizes use by the person who places the order or for whom the order was placed.

Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.

Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.




Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Non-members: Click here to review a complimentary excerpt from "Working With Patient Advocacy Groups: Effective Approaches to Advocacy Communication and Structure"

STUDY OVERVIEW

Esteemed for their dedication to improving health and providing access to relevant information, patient advocacy groups are uniquely positioned to inform and educate consumers. This benchmarking study identifies effective communication practices for bio-pharmaceutical organizations seeking to better collaborate and manage relationships with key patient advocacy groups. In addition, this study explores different organizational structures for pharma advocacy groups, as well as critical competencies for advocacy liaisons.

Best Practices, LLC designed this benchmarking study to help companies identify key benchmark metrics, executive insights and recommendations that can be used to increase effectiveness when working with patient advocacy groups. In addition it also uncovers current trends, lessons learned and pitfalls to avoid while collaborating with patient advocacy groups.

KEY TOPICS

  • Advocacy Communication Practices
  • Structuring High-Performance Bio-Pharmaceutical Advocacy Groups
  • Critical Competencies for Advocacy Liaisons
  • Current Trends and Future Directions in Patient Advocacy
  • Lessons Learned, Pitfalls and Successes

SAMPLE METRICS
  • Types of organizational structure used by pharma advocacy groups
  • Approaches used to measure effectiveness of activities for developing relationships with patient advocacy groups
  • How ensure external patient advocacy groups can contact pharma groups working in advocacy
  • Number of full time employees dedicated to patient advocacy activities
  • Average number of years of experience of employees working with patient advocacy groups
  • Issues in patient advocacy forecast to be most important in the near future
  • Types of lessons learned, pitfalls and success stories about relationships in patient advocacy


SAMPLE KEY FINDING
  • Building Infrastructures for Fast and Effective Response:

    Develop an expertise structure to support rapid response to external special interest groups – both positive and negative – to allow immediate resolution of issues and support intelligence gathering. Create a communications infrastructure for rapid response. Deputize communications leaders for hostile interactions, and centralize information management and response protocols. Stay informed through rapid global updates on hostile group activities.

    Respond locally to attacks to avoid global issue spread. Never antagonize groups whose interests diverge from yours

METHODOLOGY

Insights are drawn from survey responses from a total of 58 research participants at 43 pharmaceutical, biotechnology, and medical device companies. More than a dozen in-depth interviews were conducted to gather more detailed information pertinent to this study. Approximately half of the benchmark class (28 participants) consisted of executives representing top 50 bio-pharmaceutical companies.


Industries Profiled:
Diagnostic; Pharmaceutical; Biotech; Medical Device; Chemical; Manufacturing; Consumer Products; Health Care; Media; Service; Technology; Research


Companies Profiled:
Abaxis; Abbott Laboratories; Allos Therapeutics; Amgen; Anesiva; ANS; Astellas; Baxter; Bayer; Becton Dickinson; Boston Scientific; Bristol-Myers Squibb; Covidien; Daiichi Sankyo; Discovery Chicago; Eisai; Genentech; Genzyme; GlaxoSmithKline; IDS Canada; Infosys BPO; Johnson & Johnson; King Pharmaceuticals; Medrad; Novartis; Nupathe; Ocimum Biosolutions; Onyx Pharmaceuticals; Philips Home Healthcare; Purdue Pharma; Savient Pharmaceuticals; Solvay Pharmaceuticals; Synapse Biomedical; Takeda Pharmaceuticals; Talecris; Teva Pharmaceutical Industries Ltd; Theratechnologies; Thoratec Corporation; Tibotec; Triple-S Inc; United Therapeutics; Vital Therapies

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.